Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-two ratings firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seventeen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $656.42.
Several equities research analysts recently issued reports on PRAX shares. HC Wainwright reissued a “buy” rating on shares of Praxis Precision Medicines in a research note on Wednesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Praxis Precision Medicines in a research report on Monday, August 24th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $945.00 target price on shares of Praxis Precision Medicines in a research note on Monday, August 17th. Robert W. Baird upped their target price on Praxis Precision Medicines from $514.00 to $568.00 and gave the company an “outperform” rating in a report on Monday. Finally, Guggenheim upped their target price on Praxis Precision Medicines from $800.00 to $1,050.00 and gave the company a “buy” rating in a report on Monday.
Read Our Latest Stock Analysis on PRAX
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new position in Praxis Precision Medicines in the 2nd quarter valued at approximately $38,000. Parallel Advisors LLC lifted its position in Praxis Precision Medicines by 3,000.0% in the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock worth $40,000 after buying an additional 120 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Praxis Precision Medicines by 632.0% during the 3rd quarter. IFP Advisors Inc now owns 183 shares of the company’s stock valued at $53,000 after buying an additional 158 shares during the period. GAMMA Investing LLC boosted its stake in shares of Praxis Precision Medicines by 10.3% during the 2nd quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock valued at $111,000 after buying an additional 31 shares during the period. Finally, ABS Direct Equity Fund LLC acquired a new stake in shares of Praxis Precision Medicines during the 1st quarter valued at $135,000. 67.84% of the stock is owned by hedge funds and other institutional investors.
Praxis Precision Medicines Stock Down 5.4%
PRAX opened at $310.27 on Tuesday. The firm has a market capitalization of $8.67 billion, a P/E ratio of -24.24 and a beta of 2.85. The stock has a fifty day moving average of $289.07 and a 200-day moving average of $314.38. Praxis Precision Medicines has a 12-month low of $160.11 and a 12-month high of $392.70.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($3.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.54) by $0.31. On average, analysts expect that Praxis Precision Medicines will post -13.93 earnings per share for the current fiscal year.
Praxis Precision Medicines Company Profile
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
Featured Stories
- Five stocks we like better than Praxis Precision Medicines
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
